Supplies & Other was Tandem Diabetes Care’s largest product and service line in fiscal 2025, bringing in $550.60M of $1.01B (54%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Supplies & Other | $372.86M | $406.98M | $475.79M | $550.60M |
| Pump | $431.91M | $365.84M | $434.17M | $464.14M |
| Net Sales Recognized (Deferred) For Tandem Choice Program | — | -$25.11M | $30.25M | — |
| Net Revenue Recognized (Deferred) For Tandem Choice Program | -$3.55M | — | — | — |
| Total | $801.22M | $747.72M | $940.20M | $1.01B |
Tandem Diabetes Care brought in $1.01B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Tandem Diabetes Care regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $940.20M. Supplies & Other was the largest at $550.60M (54.3%), ahead of Pump at $464.14M (45.7%).
Compared with fiscal 2024, Supplies & Other grew 15.7% to $550.60M and Pump grew 6.9% to $464.14M.
Tandem Diabetes Care stopped reporting Net Sales Recognized (Deferred) For Tandem Choice Program as a separate line after fiscal 2024, when it brought in $30.25M.
United States was Tandem Diabetes Care’s largest region in fiscal 2025, bringing in $706.94M of $1.01B (70%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| United States | $588.77M | $554.88M | $672.69M | $706.94M | ||||
| International | — | $192.84M | $267.52M | $307.80M | ||||
| Outside The United States | $212.45M | — | — | — | ||||
| Total | $801.22M | $747.72M | $940.20M | $1.01B |
Tandem Diabetes Care brought in $1.01B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 7.9% from $940.20M in fiscal 2024. United States was the largest at $706.94M (69.7%), ahead of International at $307.80M (30.3%).
Compared with fiscal 2024, International grew 15.1% to $307.80M and United States grew 5.1% to $706.94M.
Tandem Diabetes Care stopped reporting Outside The United States as a separate region after fiscal 2022, when it brought in $212.45M.
Tandem Diabetes Care (TNDM) reports its revenue by product and service and by geography. In fiscal 2025, Supplies & Other was its largest product and service line, bringing in $550.60M (54.3% of the total), followed by Pump at $464.14M (45.7%).
Supplies & Other was Tandem Diabetes Care's largest product and service line in fiscal 2025, bringing in $550.60M, or 54.3% of the $1.01B total across its two product and service lines.
United States was Tandem Diabetes Care's largest region in fiscal 2025, bringing in $706.94M, or 69.7% of the $1.01B total across its two regions.
International grew faster than United States in fiscal 2025, up 15.1% from $267.52M to $307.80M. United States grew 5.1% to $706.94M.
Every figure comes from Tandem Diabetes Care's annual financial filings, as reported. Each line keeps the name Tandem Diabetes Care gives it, and years follow its fiscal calendar.
Tandem Diabetes Care's revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.